Cargando…
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
Over the past two decades, the natural history of multiple myeloma (MM) has evolved dramatically, owing primarily to novel agents targeting MM in the bone marrow microenvironment (BMM) pathways. However, the mechanisms of resistance acquisition remain a mystery and are poorly understood. Autophagy a...
Autores principales: | Al-Odat, Omar S., Guirguis, Daniel A., Schmalbach, Nicole K., Yao, Gabriella, Budak-Alpdogan, Tulin, Jonnalagadda, Subash C., Pandey, Manoj K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820338/ https://www.ncbi.nlm.nih.gov/pubmed/36614089 http://dx.doi.org/10.3390/ijms24010644 |
Ejemplares similares
-
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
por: Elbezanti, Weam Othman, et al.
Publicado: (2023) -
Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021) -
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2021) -
Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
por: Elbezanti, Weam Othman, et al.
Publicado: (2022) -
Promyelocytic Blast Crisis of Chronic Myeloid Leukemia in a Patient Undergoing Therapy with a Tyrosine Kinase Inhibitor
por: Parsi, Meghana, et al.
Publicado: (2020)